Altria Group, Inc. (NYSE:MO) today reports our 2023 third-quarter and nine-months business results and narrows our guidance for 2023 full-year adjusted diluted earnings per share (EPS).

"Our highly profitable traditional tobacco businesses were resilient in a dynamic operating environment during the third quarter and first nine months, providing fuel for our business transformation and significant cash returns to our shareholders," said Billy Gifford, Altria's Chief Executive Officer. "I believe we have the appropriate strategies and people in place to execute our growth plans. I continue to believe that we can achieve our Vision and create long-term value for our shareholders."

"We are narrowing our full-year 2023 guidance and now expect to deliver adjusted diluted EPS in a range of $4.91 to $4.98. This range represents an adjusted diluted EPS growth rate of 1.5% to 3% from a base of $4.84 in 2022."

Altria Headline Financials¹

($ in millions, except per share data)	Q3 2023	Change vs. Q3 2022	Q3 YTD 2023	Change vs. Q3 YTD 2022
Net revenues	$6,281	(4.1)%	$18,508	(2.5)%
Revenues net of excise taxes	$5,277	(2.5)%	$15,478	(0.8)%

Reported tax rate	25.5%	(19.5) pp	25.9%	(8.5) pp
Adjusted tax rate	24.4%	(0.5) pp	24.7%	(0.2) pp

Reported diluted EPS²	$1.22	100%+	$3.40	100%+
Adjusted diluted EPS²	$1.28	—%	$3.78	3.3%

¹ "Adjusted" financial measures presented in this release exclude the impact of special items. See "Basis of Presentation" for more information.

²"EPS" represents diluted earnings per share.

As previously announced, a conference call with the investment community and news media will be webcast on October 26, 2023 at 9:00 a.m. Eastern Time. Access to the webcast is available at www.altria.com/webcasts.

NJOY

Business Update

On June 1, 2023, we completed our acquisition of NJOY Holdings, Inc. (NJOY Transaction). Our teams executed NJOY's business plans with speed and focus during our first full quarter of ownership. NJOY is responsibly and sustainably growing the business. Our efforts are concentrated on the following:

We strengthened NJOY's global supply chain to provide sustainable support for the anticipated volume increase associated with our NJOY ACE (ACE) expansion plans. We do not anticipate capacity constraints as we execute our initial expansion plans. In addition, we are filling inventory gaps at retail and expanding distribution of ACE. We continue to expect ACE distribution to reach a total of 70,000 stores by year-end, representing approximately 70% of e-vapor volume and 55% of cigarette volume sold in the U.S. multi-outlet and convenience channel;
Generating awareness of ACE by amplifying visibility and establishing disruptive positioning at retail; and
Refining our understanding of adult vapers to inform our consumer engagement strategies.

Business Results

For the third quarter:

Reported shipment volume of ACE was approximately 7.5 million pods.
The retail share of ACE pods in U.S. multi-outlet and convenience stores was essentially unchanged since the completion of the NJOY Transaction.

Cash Returns to Shareholders

Share Repurchase Program

In the third quarter, we repurchased 5.9 million shares at an average price of $44.26, for a total cost of $260 million. Through the first nine months, we repurchased 16.3 million shares at an average price of $44.97, for a total cost of $732 million.
As of September 30, 2023, we had $268 million remaining under our current share repurchase program, which we expect to complete by December 31, 2023. Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board of Directors (Board).

Dividends

We paid dividends of $1.6 billion and $5.0 billion in the third quarter and first nine months, respectively.
In August, our Board increased our regular quarterly dividend by 4.3%, for the 58th increase in the past 54 years. Our current annualized dividend rate is $3.92 per share, representing a dividend yield of 9.2% as of October 24, 2023.
We maintain our progressive dividend goal that targets mid-single digits dividend per share growth annually. Future dividend payments remain subject to the discretion of our Board.

Environmental, Social and Governance

Our Corporate Responsibility Focus Areas are: (i) reduce the harm of tobacco products, (ii) prevent underage use, (iii) protect the environment, (iv) drive responsibility through our value chain, (v) support our people and communities and (vi) engage and lead responsibly. Our corporate responsibility reports are available on the Responsibility section of www.altria.com.

We recently published our 2022 Protect the Environment Snapshot. We are pleased to report that we are on track to meet all of our 2030 environmental targets by the end of 2023. We are now in the process of setting new environmental targets, which we expect to share early next year.
We ranked #6 on Fortune and Great Place to Work's® list of Best Workplaces in Manufacturing and Production™ for 2023. This was our third consecutive appearance on Fortune and Great Place to Work's® list.
We received a top score of 100 on the Disability Equality Index - Best Place to Work for Disability Inclusion by Disability:IN American Association of People with Disabilities.

2023 Full-Year Guidance

We narrow our guidance for 2023 full-year adjusted diluted EPS to be in a range of $4.91 to $4.98, representing a growth rate of 1.5% to 3% from an adjusted diluted EPS base of $4.84 in 2022. Our 2023 full-year adjusted diluted EPS guidance range includes planned investments in support of our Vision, such as (i) continued smoke-free product research, development and regulatory preparation expenses, (ii) enhancement of our digital consumer engagement system and (iii) marketplace activities in support of our smoke-free products, including planned investments behind the U.S. commercialization of ACE. Our guidance range also includes estimated amortization charges of approximately $50 million related to intangible assets acquired in the NJOY Transaction.

While the 2023 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. We will continue to monitor conditions related to (i) the economy, including the impact of high inflation, rising interest rates and global supply chain disruptions, (ii) adult tobacco consumer (ATC) dynamics, including disposable income, purchasing patterns and adoption of smoke-free products, and (iii) regulatory and legislative developments.

We continue to expect our 2023 full-year adjusted effective tax rate to be in a range of 24.5% to 25.5% and our 2023 capital expenditures to be between $175 million and $225 million. As a result of the NJOY Transaction, we previously revised our estimate for 2023 depreciation and amortization expenses to be approximately $280 million.

Our full-year adjusted diluted EPS guidance range and full-year forecast for our adjusted effective tax rate exclude the impact of certain income and expense items that our management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition, disposition and integration-related items, equity investment-related special items (including any changes in fair value of our equity investment recorded at fair value, certain income tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the MSA (NPM Adjustment Items). See Table 1 below for the income and expense items for the first nine months of 2023.

Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS or our effective tax rate because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding U.S. generally accepted accounting principles (GAAP) measure for, or reconciliation to, our adjusted diluted EPS guidance or our adjusted effective tax rate forecast.

ALTRIA GROUP, INC.

See "Basis of Presentation" below for an explanation of financial measures and reporting segments discussed in this release.

Financial Performance

Third Quarter

Net revenues decreased 4.1% to $6.3 billion, primarily driven by lower net revenues in the smokeable products segment. Revenues net of excise taxes decreased 2.5% to $5.3 billion.
Reported diluted EPS increased 100%+ to $1.22, primarily driven by our impairment of our investment in ABI in 2022 and 2022 charges related to our former investment in JUUL Labs, Inc. (JUUL) equity securities, partially offset by unfavorable income tax items.
Adjusted diluted EPS was unchanged at $1.28, as lower adjusted OCI was offset by fewer shares outstanding.

First Nine Months

Net revenues decreased 2.5% to $18.5 billion, primarily driven by lower net revenues in the smokeable products segment. Revenues net of excise taxes decreased 0.8% to $15.5 billion.
Reported diluted EPS increased 100%+ to $3.40, primarily driven by favorable reported results from our investment in ABI (due primarily to our impairment of our investment in ABI in 2022), lower charges related to our former investment in JUUL equity securities, favorable Cronos-related special items, fewer shares outstanding, higher reported OCI and favorable interest expense. These drivers were partially offset by higher tobacco and health and certain other litigation items, unfavorable income tax items, lower net periodic benefit income and acquisition costs related to the NJOY Transaction.
Adjusted diluted EPS increased 3.3% to $3.78, primarily driven by fewer shares outstanding, higher adjusted OCI, higher adjusted earnings from our equity investments and favorable interest expense, partially offset by lower net periodic benefit income and higher amortization due to the NJOY Transaction.

Table 1 - Altria's Adjusted Results

	Third Quarter							Nine Months Ended September 30,
	2023		2022			Change		2023		2022			Change
Reported diluted EPS	$	1.22	$	0.12		100	%+	$	3.40	$	1.69		100	%+
NPM Adjustment Items		—		—					—		(0.02	)
Tobacco and health and certain other litigation items		0.01		0.02					0.18		0.04
Loss on disposition and changes in fair value of JUUL equity securities		—		0.06					0.14		0.76
ABI-related special items		0.03		1.10					0.02		1.12
Cronos-related special items		—		—					0.02		0.09
Income tax items		0.02		(0.02	)				0.02		(0.02	)
Adjusted diluted EPS	$	1.28	$	1.28		—	%	$	3.78	$	3.66		3.3	%

Note: For details of pre-tax, tax and after-tax amounts, see Schedules 7 and 9.

Special Items

The EPS impact of the following special items is shown in Table 1 and Schedules 6, 7, 8 and 9.

NPM Adjustment Items

In the first nine months of 2022, we recorded pre-tax income of $60 million (or $0.02 per share) for NPM Adjustment Items.

Tobacco and Health and Certain Other Litigation Items

In the third quarter and first nine months of 2023, we recorded pre-tax charges of $23 million (or $0.01 per share) and $424 million (or $0.18 per share), respectively, for tobacco and health and certain other litigation items and related interest costs. The charges for the first nine months include the settlement of JUUL-related litigation.
In the third quarter and first nine months of 2022, we recorded pre-tax charges of $43 million (or $0.02 per share) and $101 million (or $0.04 per share), respectively, for tobacco and health and certain other litigation items and related interest costs.

Loss on Disposition and Changes in Fair Value of JUUL Equity Securities

As previously disclosed, we exchanged our entire minority economic interest in JUUL for a non-exclusive, irrevocable global license to certain of JUUL's heated tobacco intellectual property (2023 JUUL Transaction). We recorded non-cash, pre-tax losses from investments in equity securities as a result of the 2023 JUUL Transaction and, in 2022, changes in the estimated fair value of our former investment in JUUL. Amounts consisted of the following:

	Third Quarter				Nine Months Ended September 30,
($ in millions, except per share data)	2023		2022		2023		2022

(Income) losses from investments in equity securities	$	—	$	100	$	250	$	1,355
Losses per share	$	—	$	0.06	$	0.14	$	0.76

We recorded corresponding adjustments to the JUUL tax valuation allowance in 2023 and 2022.

ABI-Related Special Items

In the third quarter and first nine months of 2023, equity earnings from ABI included net pre-tax losses of $82 million (or $0.03 per share) and $54 million (or $0.02 per share), respectively, consisting primarily of mark-to-market losses on certain ABI financial instruments associated with its share commitments.
In the third quarter and first nine months of 2022, equity earnings from ABI included net pre-tax losses of $2.5 billion (or $1.10 per share) and $2.6 billion (or $1.12 per share), respectively, substantially all of which related to our impairment of our investment in ABI.

The ABI-related special items above include our respective share of the amounts recorded by ABI and additional adjustments related to (i) conversion from international financial reporting standards to GAAP and (ii) adjustments to our investment required under the equity method of accounting.

Cronos-Related Special Items

We recorded net pre-tax expense consisting of the following:

	Third Quarter				Nine Months Ended September 30,
($ in millions, except per share data)	2023		2022		2023		2022

Loss on Cronos-related financial instruments	$	—	$	—	$	—	$	14
(Income) losses from investments in equity securities¹		—		5		30		166
Total Cronos-related special items - (income) expense	$	—	$	5	$	30	$	180
Losses per share	$	—	$	—	$	0.02	$	0.09

¹ Amounts include our share of special items recorded by Cronos and additional adjustments, if required under the equity method of accounting, related to our investment in Cronos including the $107 million non-cash pre-tax impairment of our investment in Cronos in the second quarter of 2022.

We recorded corresponding adjustments to the Cronos tax valuation allowance in 2023 and 2022 relating to the special items.

Income Tax Items

In the third quarter and first nine months of 2023, we recorded income tax items of $29 million (or $0.02 per share), due primarily to tax expense associated with a tax basis adjustment related to our investment in ABI.
In the third quarter and first nine months of 2022, we recorded income tax items of $42 million (or $0.02 per share) and $33 million (or $0.02 per share), respectively, due primarily to tax benefits associated with the release of a valuation allowance related to our prior Cronos warrant, partially offset by tax expense for tax reserves related to the disallowance of certain state tax credits.

SMOKEABLE PRODUCTS

Revenues and OCI

Third Quarter

Net revenues decreased 5.3%, primarily driven by lower shipment volume and higher promotional investments, partially offset by higher pricing. Revenues net of excise taxes decreased 3.7%.
Reported OCI decreased 1.7%, primarily driven by lower shipment volume, higher promotional investments and higher costs, partially offset by higher pricing and NPM Adjustment Items in 2023.
Adjusted OCI decreased 2.5%, primarily driven by lower shipment volume, higher promotional investments and higher costs, partially offset by higher pricing. Adjusted OCI margins increased by 0.7 percentage points to 59.6%.

First Nine Months

Net revenues decreased 3.2%, primarily driven by lower shipment volume and higher promotional investments, partially offset by higher pricing. Revenues net of excise taxes decreased 1.4%.
Reported OCI decreased 0.2%, primarily driven by lower shipment volume, higher promotional investments, higher per unit settlement charges, higher costs and lower NPM Adjustment Items, partially offset by higher pricing.
Adjusted OCI increased 0.2%, primarily driven by higher pricing, partially offset by lower shipment volume, higher promotional investments, higher per unit settlement charges and higher costs. Adjusted OCI margins increased by 0.9 percentage points to 60.1%.

Table 2 - Smokeable Products: Revenues and OCI ($ in millions)

	Third Quarter								Nine Months Ended September 30,
	2023			2022			Change		2023			2022			Change
Net revenues	$	5,572		$	5,882		(5.3	)%	$	16,482		$	17,020		(3.2	)%
Excise taxes		(976	)		(1,108	)				(2,945	)		(3,289	)
Revenues net of excise taxes	$	4,596		$	4,774		(3.7	)%	$	13,537		$	13,731		(1.4	)%

Reported OCI	$	2,743		$	2,791		(1.7	)%	$	8,092		$	8,112		(0.2	)%
NPM Adjustment Items		(15	)		—					(15	)		(60	)
Tobacco and health and certain other litigation items		13			21					65			71
Adjusted OCI	$	2,741		$	2,812		(2.5	)%	$	8,142		$	8,123		0.2	%
Reported OCI margins ¹		59.7	%		58.5	%	1.2 pp			59.8	%		59.1	%	0.7 pp
Adjusted OCI margins ¹		59.6	%		58.9	%	0.7 pp			60.1	%		59.2	%	0.9 pp

¹ Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

Third Quarter

Smokeable products segment reported domestic cigarette shipment volume decreased 11.6%, primarily driven by the industry's decline rate (impacted by macroeconomic pressures on ATC disposable income and the growth of illicit e-vapor products), retail share losses, calendar differences and trade inventory movements.
When adjusted for calendar differences and trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 10%.
When adjusted for trade inventory movements, calendar differences and other factors, total estimated domestic cigarette industry volume decreased by an estimated 8%.
Reported cigar shipment volume increased 2.7%.

First Nine Months

Smokeable products segment reported and adjusted domestic cigarette shipment volume decreased 10.5%, primarily driven by the industry's decline rate (impacted by macroeconomic pressures on ATC disposable income and the growth of illicit e-vapor products) and retail share losses.
When adjusted for trade inventory movements and other factors, total estimated domestic cigarette industry volume decreased by an estimated 8%.
Reported cigar shipment volume increased 4.2%.

Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)

	Third Quarter				Nine Months Ended September 30,
	2023	2022	Change		2023	2022	Change
Cigarettes:
*Marlboro*	17,437	19,484	(10.5	)%	52,339	57,809	(9.5	)%
Other premium	895	997	(10.2	)%	2,674	2,951	(9.4	)%
Discount	970	1,364	(28.9	)%	3,119	4,211	(25.9	)%
Total cigarettes	19,302	21,845	(11.6	)%	58,132	64,971	(10.5	)%

Cigars:
*Black & Mild*	451	438	3.0	%	1,359	1,303	4.3	%
Other	—	1	(100.0	)%	2	3	(33.3	)%
Total cigars	451	439	2.7	%	1,361	1,306	4.2	%

Total smokeable products	19,753	22,284	(11.4	)%	59,493	66,277	(10.2	)%

Note: Cigarettes volume includes units sold as well as promotional units but excludes units sold for distribution to Puerto Rico, U.S. Territories to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to our smokeable products segment.

Retail Share and Brand Activity

Third Quarter

Marlboro retail share of the total cigarette category was 42.3%, a decrease of 0.3 share points versus the prior year, primarily due to increased macroeconomic pressures on ATC disposable income and increased competitive activity. Marlboro retail share increased 0.3 share points from the second quarter of 2023 (Marlboro retail share for the second quarter of 2023 was revised to 42.0 from 42.1, based upon the most recent periodic data refresh from Circana). Additionally, Marlboro share of the premium segment was 58.9%, an increase of 0.4 share points versus the prior year and 0.3 share points sequentially.
The cigarette industry discount retail share was 28.2%, an increase of 1.1 share points versus the prior year primarily due to the ATC factors mentioned above. Cigarette industry discount retail share was unchanged from the first and second quarter of 2023.

First Nine Months

Marlboro retail share of the total cigarette category was 42.1%, a decrease of 0.6 share points versus the prior year primarily due to increased macroeconomic pressures on ATC disposable income and increased competitive activity.
The cigarette industry discount retail share was 28.2%, an increase of 1.6 share points versus the prior year due to the ATC factors mentioned above.

Table 4 - Smokeable Products: Cigarettes Retail Share (percent)

	Third Quarter						Nine Months Ended September 30,
	2023		2022		Percentage point change		2023		2022		Percentage point change
Cigarettes:
*Marlboro*	42.3	%	42.6	%	(0.3	)	42.1	%	42.7	%	(0.6	)
Other premium	2.3		2.3		—		2.3		2.3		—
Discount	2.4		3.0		(0.6	)	2.6		3.1		(0.5	)
Total cigarettes	47.0	%	47.9	%	(0.9	)	47.0	%	48.1	%	(1.1	)

Note: Retail share results for cigarettes are based on data from Circana, Inc. and Circana Group, L.P. ("Circana") as well as, MSAi. Circana is a newly formed company reflecting the recent merger of IRI and NPD Group, Inc. Circana maintains a blended retail service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. Similar to prior reporting, this service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System ("STARS"), as provided by MSAi. This service is not designed to capture sales through other channels, including the internet, direct mail and some illicitly tax-advantaged outlets. It is retail services' standard practice to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

ORAL TOBACCO PRODUCTS

Revenues and OCI

Third Quarter

Net revenues increased 2.2%, primarily driven by higher pricing and lower promotional investments, partially offset by lower MST shipment volume and a higher percentage of on! shipment volume relative to MST versus the prior year (mix change). Revenues net of excise taxes increased 2.7%.
Reported and adjusted OCI increased 7.1%, primarily driven by higher pricing, lower costs and lower promotional investments, partially offset by lower MST shipment volume and mix change. Adjusted OCI margins increased by 2.9 percentage points to 69.3%.

First Nine Months

Net revenues increased 2.3%, primarily driven by higher pricing, partially offset by lower MST shipment volume, mix change and higher promotional investments. Revenues net of excise taxes increased 2.7%.
Reported and adjusted OCI increased 4.1%, primarily driven by higher pricing and lower costs, partially offset by lower MST shipment volume, mix change and higher promotional investments. Adjusted OCI margins increased by 0.9 percentage points to 68.9%.

Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)

	Third Quarter								Nine Months Ended September 30,
	2023			2022			Change		2023			2022			Change
Net revenues	$	685		$	670		2.2	%	$	1,993		$	1,948		2.3	%
Excise taxes		(28	)		(30	)				(85	)		(91	)
Revenues net of excise taxes	$	657		$	640		2.7	%	$	1,908		$	1,857		2.7	%

Reported and adjusted OCI	$	455		$	425		7.1	%	$	1,314		$	1,262		4.1	%
Reported and adjusted OCI margins ¹		69.3	%		66.4	%	2.9 pp			68.9	%		68.0	%	0.9 pp

¹ Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

Third Quarter

Oral tobacco products segment reported domestic shipment volume decreased 3.3%, primarily driven by retail share losses in MST and calendar differences, partially offset by the industry's growth rate and other factors. When adjusted for calendar differences, oral tobacco products segment shipment volume decreased by an estimated 2%.

First Nine Months

Oral tobacco products segment reported domestic shipment volume decreased 2.3%, primarily driven by retail share losses in MST, partially offset by the industry's growth rate, calendar differences, trade inventory movements and other factors. When adjusted for calendar differences and trade inventory movements, oral tobacco products segment shipment volume decreased by an estimated 2.5%.
Total oral tobacco industry volume increased by an estimated 5% for the six months ended September 30, 2023, primarily driven by growth in oral nicotine pouches, partially offset by declines in MST volumes.

Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)

	Third Quarter				Nine Months Ended September 30,
	2023	2022	Change		2023	2022	Change
*Copenhagen*	109.4	118.2	(7.4	)%	333.3	356.5	(6.5	)%
*Skoal*	40.4	45.3	(10.8	)%	123.3	136.1	(9.4	)%
*on!*	28.7	21.0	36.7	%	83.9	59.6	40.8	%
Other	16.3	16.9	(3.6	)%	49.3	51.3	(3.9	)%
Total oral tobacco products	194.8	201.4	(3.3	)%	589.8	603.5	(2.3	)%

Note: Volume includes cans and packs sold, as well as promotional units, but excludes international volume, which is currently not material to our oral tobacco products segment. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans and packs shipped, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack, is assumed to be equivalent to one can of MST.

Retail Share and Brand Activity

Third Quarter

Oral tobacco products segment retail share was 42.1%, as share declines for MST products were primarily driven by the category share growth of oral nicotine pouches.
Total U.S. oral tobacco category share for on! nicotine pouches was 6.9%, an increase of 1.7 percentage points versus the prior year, and was stable sequentially.
The U.S. nicotine pouch category grew to 32.3% of the U.S. oral tobacco category, an increase of 9.8 share points versus the prior year. In addition, on!'s share of the nicotine pouch category was 21.4%.

First Nine Months

Oral tobacco products segment retail share was 43.7%, as share declines for MST products were primarily driven by the category share growth of oral nicotine pouches.
Total U.S. oral tobacco category share for on! nicotine pouches was 6.8%, an increase of 2.1 percentage points.

Table 7 - Oral Tobacco Products: Retail Share (percent)

	Third Quarter						Nine Months Ended September 30,
	2023		2022		Percentage point change		2023		2022		Percentage point change
*Copenhagen*	23.1	%	26.8	%	(3.7	)	24.2	%	27.4	%	(3.2	)
*Skoal*	9.3		11.1		(1.8	)	9.8		11.4		(1.6	)
*on!*	6.9		5.2		1.7		6.8		4.7		2.1
Other	2.8		3.2		(0.4	)	2.9		3.2		(0.3	)
Total oral tobacco products	42.1	%	46.3	%	(4.2	)	43.7	%	46.7	%	(3.0	)

Note: Our oral tobacco products segment's retail share results exclude international volume. Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans and packs sold. Oral tobacco products are defined by Circana as moist smokeless, snus and oral nicotine pouches. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. For example, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack, is assumed to be equivalent to one can of MST. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is retail services' standard practice to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

Altria's Profile

We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. Our Vision is to responsibly lead the transition of adult smokers to a smoke-free future (Vision). We are Moving Beyond Smoking™, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), currently the only e-vapor manufacturer to receive market authorizations from the U.S. Food and Drug Administration (FDA) for a pod-based e-vapor product.

Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products and, through a separate agreement, we have the exclusive U.S. commercialization rights to the IQOS Tobacco Heating System® and Marlboro HeatSticks® through April 2024.

Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world's largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

Learn more about Altria at www.altria.com and follow us on X (formerly known as Twitter), Facebook and LinkedIn.

Basis of Presentation

We report our financial results in accordance with GAAP. Our management reviews OCI, which is defined as operating income before general corporate expenses and amortization of intangibles, to evaluate the performance of, and allocate resources to, our segments. Our management also reviews certain financial results, including OCI, OCI margins and diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under "2023 Full-Year Guidance." Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management also reviews income tax rates on an adjusted basis. Our adjusted effective tax rate may exclude certain income tax items from our reported effective tax rate. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with, GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. We provide reconciliations of historical adjusted financial measures to corresponding GAAP measures in this release.

We use the equity method of accounting for our investment in ABI and Cronos and report our share of ABI's and Cronos's results using a one-quarter lag because ABI's and Cronos's results are not available in time for us to record them in the concurrent period. The one-quarter reporting lag for ABI and Cronos does not affect our cash flows. We accounted for our former investment in the equity securities of JUUL at fair value.

Our reportable segments are (i) smokeable products, including combustible cigarettes and cigars manufactured and sold by PM USA and Middleton, respectively, and (ii) oral tobacco products, including MST and snus products manufactured and sold by USSTC, and oral nicotine pouches sold by Helix. We have included results for NJOY, Helix rest-of-world, the IQOS Tobacco Heating System® and Philip Morris Capital Corporation (prior to the completion of its wind-down at the end of 2022) in "All Other." Comparisons are to the corresponding prior-year period unless otherwise stated.

Forward-Looking and Cautionary Statements

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Important factors that may cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2022 and our Quarterly Reports on Form 10-Q. These factors include the following:

our inability to anticipate and respond to changes in adult tobacco consumer preferences and purchase behavior;

our inability to compete effectively;

the growth of the e-vapor category, including illegal flavored disposable e-vapor products, and other innovative tobacco products, including oral nicotine pouches, contributing to reductions in cigarette and MST consumption levels and shipment volume;

our failure to commercialize innovative products, including tobacco products that may reduce health risks relative to other tobacco products and appeal to adult tobacco consumers;

changes, including in macroeconomic and geopolitical conditions (including inflation), that result in shifts in adult tobacco consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;

unfavorable outcomes with respect to litigation proceedings or any governmental investigations;

the risks associated with significant federal, state and local government actions, including FDA regulatory actions, and various private sector actions;

increases in tobacco product-related taxes;

our failure to complete or manage successfully strategic transactions, including the NJOY Transaction and other acquisitions, dispositions, joint ventures and investments in third parties, or realize the anticipated benefits of such transactions;

significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions;

our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;

the risk that we may be required to write down intangible assets, including trademarks and goodwill, due to impairment;

the risk that we could decide, or be required to, recall products;

the various risks related to health epidemics and pandemics, such as the COVID-19 pandemic, and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;

our inability to attract and retain a highly skilled and diverse workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;

the risks associated with the various U.S. and foreign laws and regulations to which we are subject due to our international business operations;

the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;

the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;

disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;

a downgrade or potential downgrade of our credit ratings;

our inability to attract investors due to increasing investor expectations of our performance relating to environmental, social and governance factors;

the failure of our, or our key service providers' or key suppliers', information systems to function as intended, or cyber-attacks or security breaches;

our failure to comply with personal data protection and privacy laws;

the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all, including due to macroeconomic and geopolitical conditions; foreign currency exchange rates; ABI's business results; ABI's share price; impairment losses on the value of our investment; our incurrence of additional tax liabilities related to our investment in ABI; and potential reductions in the number of directors that we can have appointed to the ABI board of directors; and

the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected timeframe or at all.

You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

		Schedule 1
ALTRIA GROUP, INC.
and Subsidiaries
Consolidated Statements of Earnings
For the Quarters Ended September 30,
(dollars in millions, except per share data)
(Unaudited)

	2023			2022			% Change

Net revenues	$	6,281		$	6,550		(4.1	)%
Cost of sales ¹		1,578			1,715
Excise taxes on products ¹		1,004			1,138
Gross profit		3,699			3,697		0.1	%
Marketing, administration and research costs		505			488
Operating companies income		3,194			3,209		(0.5	)%
Amortization of intangibles		42			19
General corporate expenses		63			78
Operating income		3,089			3,112		(0.7	)%
Interest and other debt expense, net		272			271
Net periodic benefit income, excluding service cost		(33	)		(44	)
(Income) losses from investments in equity securities ¹		(58	)		2,478
Earnings before income taxes		2,908			407		100	%+
Provision for income taxes		742			183
Net earnings	$	2,166		$	224		100	%+

Per share data:
Diluted earnings per share	$	1.22		$	0.12		100	%+

Weighted-average diluted shares outstanding		1,773			1,799		(1.4	)%

¹ Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5.

Schedule 2
ALTRIA GROUP, INC.
and Subsidiaries
Selected Financial Data
For the Quarters Ended September 30,
(dollars in millions)
(Unaudited)


	Net Revenues
	Smokeable Products			Oral Tobacco Products			All Other			Total
2023	$	5,572		$	685		$	24		$	6,281
2022		5,882			670			(2	)		6,550
% Change		(5.3	)%		2.2	%		100	%+		(4.1	)%

Reconciliation:
For the quarter ended September 30, 2022	$	5,882		$	670		$	(2	)	$	6,550
Operations		(310	)		15			26			(269	)
For the quarter ended September 30, 2023	$	5,572		$	685		$	24		$	6,281

	Operating Companies Income (Loss)
	Smokeable Products			Oral Tobacco Products			All Other			Total
2023	$	2,743		$	455		$	(4	)	$	3,194
2022		2,791			425			(7	)		3,209
% Change		(1.7	)%		7.1	%		42.9	%		(0.5	)%

Reconciliation:
For the quarter ended September 30, 2022	$	2,791		$	425		$	(7	)	$	3,209

Tobacco and health and certain other litigation items - 2022		21			—			—			21
		21			—			—			21

NPM Adjustment Items - 2023		15			—			—			15
Tobacco and health and certain other litigation items - 2023		(13	)		—			—			(13	)
		2			—			—			2
Operations		(71	)		30			3			(38	)
For the quarter ended September 30, 2023	$	2,743		$	455		$	(4	)	$	3,194

Schedule 3
ALTRIA GROUP, INC.
and Subsidiaries
Consolidated Statements of Earnings
For the Nine Months Ended September 30,
(dollars in millions, except per share data)
(Unaudited)


	2023			2022			% Change

Net revenues	$	18,508		$	18,985		(2.5	)%
Cost of sales ¹		4,693			4,869
Excise taxes on products¹		3,030			3,380
Gross profit		10,785			10,736		0.5	%
Marketing, administration and research costs		1,396			1,389
Operating companies income		9,389			9,347		0.4	%
Amortization of intangibles		87			54
General corporate expenses		551			192
Operating income		8,751			9,101		(3.8	)%
Interest and other debt expense, net		758			832
Net periodic benefit income, excluding service cost		(95	)		(137	)
(Income) losses from investments in equity securities ¹		(105	)		3,707
Loss on Cronos-related financial instruments		—			14
Earnings before income taxes		8,193			4,685		74.9	%
Provision for income taxes		2,123			1,611
Net earnings	$	6,070		$	3,074		97.5	%

Per share data²:
Diluted earnings per share	$	3.40		$	1.69		100	%+

Weighted-average diluted shares outstanding		1,780			1,808		(1.5	)%

¹ Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5.

² Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.

Schedule 4
ALTRIA GROUP, INC.
and Subsidiaries
Selected Financial Data
For the Nine Months Ended September 30,
(dollars in millions)
(Unaudited)


	Net Revenues
	Smokeable Products			Oral Tobacco Products			All Other			Total
2023	$	16,482		$	1,993		$	33		$	18,508
2022		17,020			1,948			17			18,985
% Change		(3.2	)%		2.3	%		94.1	%		(2.5	)%

Reconciliation:
For the nine months ended September 30, 2022	$	17,020		$	1,948		$	17		$	18,985
Operations		(538	)		45			16			(477	)
For the nine months ended September 30, 2023	$	16,482		$	1,993		$	33		$	18,508

	Operating Companies Income (Loss)
	Smokeable Products			Oral Tobacco Products			All Other			Total
2023	$	8,092		$	1,314		$	(17	)	$	9,389
2022		8,112			1,262			(27	)		9,347
% Change		(0.2	)%		4.1	%		37.0	%		0.4	%

Reconciliation:
For the nine months ended September 30, 2022	$	8,112		$	1,262		$	(27	)	$	9,347

NPM Adjustment Items - 2022		(60	)		—			—			(60	)
Tobacco and health and certain other litigation items - 2022		71			—			—			71
		11			—			—			11

NPM Adjustment Items - 2023		15			—			—			15
Tobacco and health and certain other litigation items - 2023		(65	)		—			—			(65	)
		(50	)		—			—			(50	)
Operations		19			52			10			81
For the nine months ended September 30, 2023	$	8,092		$	1,314		$	(17	)	$	9,389

Schedule 5
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data
(dollars in millions)
(Unaudited)


	For the Quarters Ended September 30,					For the Nine Months Ended September 30,
	2023			2022		2023			2022
The segment detail of excise taxes on products sold is as follows:

Smokeable products	$	976		$	1,108	$	2,945		$	3,289
Oral tobacco products		28			30		85			91
	$	1,004		$	1,138	$	3,030		$	3,380


The segment detail of charges for resolution expenses related to state settlement agreements included in cost of sales is as follows:

Smokeable products	$	921		$	1,053	$	2,832		$	2,986
Oral tobacco products		—			2		3			7
	$	921		$	1,055	$	2,835		$	2,993


The segment detail of FDA user fees included in cost of sales is as follows:

Smokeable products	$	63		$	67	$	193		$	204
Oral tobacco products		2			2		4			4
	$	65		$	69	$	197		$	208


The detail of (income) losses from investments in equity securities is as follows:

ABI	$	(61	)	$	2,367	$	(401	)	$	2,155
Cronos		3			11		46			197
JUUL		—			100		250			1,355
	$	(58	)	$	2,478	$	(105	)	$	3,707

Schedule 6
ALTRIA GROUP, INC.
and Subsidiaries
Net Earnings and Diluted Earnings Per Share
For the Quarters Ended September 30,
(dollars in millions, except per share data)
(Unaudited)


	Net Earnings			Diluted EPS
2023 Net Earnings	$	2,166		$	1.22
2022 Net Earnings	$	224		$	0.12
% Change		100	%+		100	%+

Reconciliation:
2022 Net Earnings	$	224		$	0.12

2022 Acquisition, disposition and integration-related items		1			—
2022 Tobacco and health and certain other litigation items		32			0.02
2022 JUUL changes in fair value		100			0.06
2022 ABI-related special items		1,980			1.10
2022 Cronos-related special items		5			—
2022 Income tax items		(42	)		(0.02	)
Subtotal 2022 special items		2,076			1.16

2023 NPM Adjustment Items		11			—
2023 Acquisition, disposition and integration-related items		(9	)		—
2023 Tobacco and health and certain other litigation items		(17	)		(0.01	)
2023 ABI-related special items		(65	)		(0.03	)
2023 Income tax items		(29	)		(0.02	)
Subtotal 2023 special items		(109	)		(0.06	)

Fewer shares outstanding		—			0.01
Change in tax rate		14			0.01
Operations		(39	)		(0.02	)
2023 Net Earnings	$	2,166		$	1.22

Schedule 7
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Quarters Ended September 30,
(dollars in millions, except per share data)
(Unaudited)


	Earnings before Income Taxes			Provision for Income Taxes				Net Earnings				Diluted EPS
2023 Reported	$	2,908		$	742			$	2,166			$	1.22
NPM Adjustment Items		(15	)		(4	)			(11	)			—
Acquisition, disposition and integration-related items		13			4				9				—
Tobacco and health and certain other litigation items		23			6				17				0.01
ABI-related special items		82			17				65				0.03
Income tax items		—			(29	)			29				0.02
2023 Adjusted for Special Items	$	3,011		$	736			$	2,275			$	1.28

2022 Reported	$	407		$	183			$	224			$	0.12
Acquisition, disposition and integration-related items		1			—				1				—
Tobacco and health and certain other litigation items		43			11				32				0.02
JUUL changes in fair value		100			—				100				0.06
ABI-related special items		2,507			527				1,980				1.10
Cronos-related special items		5			—				5				—
Income tax items		—			42				(42	)			(0.02	)
2022 Adjusted for Special Items	$	3,063		$	763			$	2,300			$	1.28

2023 Reported Net Earnings								$	2,166			$	1.22
2022 Reported Net Earnings								$	224			$	0.12
% Change							100%+				100%+

2023 Net Earnings Adjusted for Special Items								$	2,275			$	1.28
2022 Net Earnings Adjusted for Special Items								$	2,300			$	1.28
% Change									(1.1	)%			—	%

Schedule 8
ALTRIA GROUP, INC.
and Subsidiaries
Net Earnings and Diluted Earnings Per Share
For the Nine Months Ended September 30,
(dollars in millions, except per share data)
(Unaudited)


	Net Earnings			Diluted EPS¹
2023 Net Earnings	$	6,070		$	3.40
2022 Net Earnings	$	3,074		$	1.69
% Change		97.5	%		100	%+

Reconciliation:
2022 Net Earnings	$	3,074		$	1.69

2022 NPM Adjustment Items		(45	)		(0.02	)
2022 Acquisition, disposition and integration-related items		8			—
2022 Tobacco and health and certain other litigation items		76			0.04
2022 JUUL changes in fair value		1,355			0.76
2022 ABI-related special items		2,022			1.12
2022 Cronos-related special items		172			0.09
2022 Income tax items		(33	)		(0.02	)
Subtotal 2022 special items		3,555			1.97

2023 NPM Adjustment Items		11			—
2023 Acquisition, disposition and integration-related items		(10	)		—
2023 Tobacco and health and certain other litigation items		(318	)		(0.18	)
2023 Loss on disposition of JUUL equity securities		(250	)		(0.14	)
2023 ABI-related special items		(43	)		(0.02	)
2023 Cronos-related special items		(30	)		(0.02	)
2023 Income tax items		(29	)		(0.02	)
Subtotal 2023 special items		(669	)		(0.38	)

Fewer shares outstanding		—			0.06
Change in tax rate		21			0.01
Operations		89			0.05
2023 Net Earnings	$	6,070		$	3.40

¹Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.

Schedule 9
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Nine Months Ended September 30,
(dollars in millions, except per share data)
(Unaudited)


	Earnings before Income Taxes			Provision for Income Taxes			Net Earnings			Diluted EPS¹
2023 Reported	$	8,193		$	2,123		$	6,070		$	3.40
NPM Adjustment Items		(15	)		(4	)		(11	)		—
Acquisition, disposition and integration-related items		14			4			10			—
Tobacco and health and certain other litigation items		424			106			318			0.18
Loss on disposition of JUUL equity securities		250			—			250			0.14
ABI-related special items		54			11			43			0.02
Cronos-related special items		30			—			30			0.02
Income tax items		—			(29	)		29			0.02
2023 Adjusted for Special Items	$	8,950		$	2,211		$	6,739		$	3.78

2022 Reported	$	4,685		$	1,611		$	3,074		$	1.69
NPM Adjustment Items		(60	)		(15	)		(45	)		(0.02	)
Acquisition, disposition and integration-related items		10			2			8			—
Tobacco and health and certain other litigation items		101			25			76			0.04
JUUL changes in fair value		1,355			—			1,355			0.76
ABI-related special items		2,560			538			2,022			1.12
Cronos-related special items		180			8			172			0.09
Income tax items		—			33			(33	)		(0.02	)
2022 Adjusted for Special Items	$	8,831		$	2,202		$	6,629		$	3.66

2023 Reported Net Earnings							$	6,070		$	3.40
2022 Reported Net Earnings							$	3,074		$	1.69
% Change								97.5	%		100	%+

2023 Net Earnings Adjusted for Special Items							$	6,739		$	3.78
2022 Net Earnings Adjusted for Special Items							$	6,629		$	3.66
% Change								1.7	%		3.3	%

¹Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.

Schedule 10
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Year Ended December 31, 2022
(dollars in millions, except per share data)
(Unaudited)


	Earnings before Income Taxes			Provision for Income Taxes			Net Earnings			Diluted EPS
2022 Reported	$	7,389		$	1,625		$	5,764		$	3.19
NPM Adjustment Items		(68	)		(17	)		(51	)		(0.03	)
Acquisition, disposition and integration-related items		11			2			9			—
Tobacco and health and certain other litigation items		131			33			98			0.05
JUUL changes in fair value		1,455			—			1,455			0.81
ABI-related special items		2,544			534			2,010			1.12
Cronos-related special items		186			—			186			0.10
Income tax items		—			729			(729	)		(0.40	)
2022 Adjusted for Special Items	$	11,648		$	2,906		$	8,742		$	4.84

Schedule 11
ALTRIA GROUP, INC.
and Subsidiaries
Condensed Consolidated Balance Sheets
(dollars in millions)
(Unaudited)


	September 30, 2023			December 31, 2022
Assets
Cash and cash equivalents	$	1,537		$	4,030
Receivable from the sale of IQOS System commercialization rights		—			1,721
Inventories		1,174			1,180
Other current assets		679			289
Property, plant and equipment, net		1,629			1,608
Goodwill and other intangible assets, net		20,518			17,561
Investments in equity securities		9,907			9,600
Other long-term assets		1,025			965
Total assets	$	36,469		$	36,954

Liabilities and Stockholders' Equity (Deficit)
Current portion of long-term debt	$	1,121		$	1,556
Accrued settlement charges		2,388			2,925
Deferred gain from the sale of IQOS System commercialization rights (current)		2,700			—
Other current liabilities		4,172			4,135
Long-term debt		23,977			25,124
Deferred income taxes		2,527			2,897
Accrued pension costs		127			133
Accrued postretirement health care costs		1,096			1,083
Deferred gain from the sale of IQOS System commercialization rights (long-term)		—			2,700
Other long-term liabilities		1,718			324
Total liabilities		39,826			40,877
Total stockholders' equity (deficit) attributable to Altria		(3,407	)		(3,973	)
Noncontrolling interest		50			50
Total liabilities and stockholders' equity (deficit)	$	36,469		$	36,954

Total debt	$	25,098		$	26,680

Schedule 12
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data for Special Items
For the Quarters Ended September 30,
(dollars in millions)
(Unaudited)


	Cost of Sales			Marketing, administration and research costs		General corporate expenses		Interest and other debt (income) expense, net			(Income) losses from investments in equity securities
2023 Special Items - (Income) Expense
NPM Adjustment Items	$	(15	)	$	—	$	—	$	—		$	—
Acquisition, disposition and integration-related items		—			—		15		(2	)		—
Tobacco and health and certain other litigation items		—			13		10		—			—
ABI-related special items		—			—		—		—			82

2022 Special Items - (Income) Expense
Acquisition, disposition and integration-related items	$	—		$	—	$	1	$	—		$	—
Tobacco and health and certain other litigation items		—			21		20		2			—
JUUL changes in fair value		—			—		—		—			100
ABI-related special items		—			—		—		—			2,507
Cronos-related special items		—			—		—		—			5

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria's consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

Schedule 13
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data for Special Items
For the Nine Months Ended September 30,
(dollars in millions)
(Unaudited)


	Cost of Sales			Marketing, administration and research costs		General corporate expenses		Interest and other debt (income) expense, net			(Income) losses from investments in equity securities		Loss on Cronos-related financial instruments
2023 Special Items - (Income) Expense
NPM Adjustment Items	$	(15	)	$	—	$	—	$	—		$	—	$	—
Acquisition, disposition and integration-related items		—			—		59		(45	)		—		—
Tobacco and health and certain other litigation items		—			65		348		11			—		—
Loss on disposition of JUUL equity securities		—			—		—		—			250		—
ABI-related special items		—			—		—		—			54		—
Cronos-related special items		—			—		—		—			30		—

2022 Special Items - (Income) Expense
NPM Adjustment Items	$	(60	)	$	—	$	—	$	—		$	—	$	—
Acquisition, disposition and integration-related items		—			—		10		—			—		—
Tobacco and health and certain other litigation items		—			71		27		3			—		—
JUUL changes in fair value		—			—		—		—			1,355		—
ABI-related special items		—			—		—		—			2,560		—
Cronos-related special items		—			—		—		—			166		14

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in our consolidated statements of earnings (losses). This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231025994449/en/

Altria Reports 2023 Third-Quarter and Nine-Months Results; Narrows 2023 Full-Year Earnings Guidance